Shareholder Votes

HF Foods Group Inc. shareholders approved Advisory Vote on Say-on-Pay Frequency at the 2026-06-05 meeting.

“The stockholders approved, on a non-binding and advisory basis, holding the advisory vote on compensation paid to the Company’s named executive officers every year. The final voting results for the Say-on-Pay Frequency Proposal were as follows: One Year Two Years Three Years Abstentions 26,643,323 56 13,017,869 1,433”

HF Foods Group Inc. shareholders rejected Say-on-Pay Proposal at the 2026-06-05 meeting.

“By advisory vote of the stockholders, the Company’s executive compensation for the year ended December 31, 2025 was not approved. The final voting results for the Say-on-Pay Proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 19,545,712 20,055,744 61,225 4,362,333”

HF Foods Group Inc. shareholders approved Auditor Ratification Proposal at the 2026-06-05 meeting.

“The appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was ratified by the stockholders. The final voting results for the Auditor Ratification Proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 42,711,453 1,309,462 4,099 —”

HF Foods Group Inc. shareholders approved Director Election Proposal at the 2026-06-05 meeting.

“The final voting results for the Director Election Proposal were as follows: Director Nominee Votes For Votes Against Abstentions Broker Non-Votes Xi "Felix" Lin 19,629,099 20,020,113 13,469 4,362,333 Richard Diaz 19,913,312 19,687,949 61,420 4,362,333 Dennis Lam 21,792,225 17,280,472 589,984 4,362,333 Jeffery Taylor 19,194,335 20,466,587 1,759 4,362,333”

PLIANT THERAPEUTICS, INC. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.

“Proposal No. 3: The Company’s stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results are as follows: For Against Abstain 41,710,604 747,140 69,239 There were no broker non-votes for Proposal No. 3.”

PLIANT THERAPEUTICS, INC. shareholders approved Non-binding advisory vote to approve the compensation of the Company’s named executive officers at the 2026-06-11 meeting.

“Proposal No. 2: The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The voting results are as follows: For Against Abstain 15,282,788 14,572,455 776,605 The broker non-votes for Proposal No. 2 totaled 11,895,135 shares of common stock.”

PLIANT THERAPEUTICS, INC. shareholders approved Election of three Class III directors to serve until the 2029 Annual Meeting at the 2026-06-11 meeting.

“Proposal No. 1: The Company’s stockholders approved the election of each of the aforementioned Class III director nominees to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal. The voting results are as follows: Nominee For Withhold Bernard Coulie, M.D., Ph.D., MBA 18,824,540 11,807,308 Gayle Crowell 18,186,914 12,444,934 Steve Krognes, MBA 19,299,728 11,332,120 The broker non-votes for Proposal No. 1 totaled 11,895,135 shares of common stock.”

WESTERN ALLIANCE BANCORPORATION shareholders approved Ratification of Auditor at the 2026-06-10 meeting.

“ratified the appointment of RSM US LLP as the Company's independent auditor for the fiscal year ending December 31, 2026”

WESTERN ALLIANCE BANCORPORATION shareholders approved Advisory (Non-Binding) Vote on Executive Compensation at the 2026-06-10 meeting.

“approved the non-binding advisory vote on executive compensation”

WESTERN ALLIANCE BANCORPORATION shareholders approved Election of Directors at the 2026-06-10 meeting.

“elected all of the thirteen nominees for director”

Idaho Strategic Resources, Inc. shareholders approved Ratification of the appointment of Assure, CPA, LLC as independent registered public accounting firm for the ensuing year at the 2026-06-10 meeting.

“Proposal 2 – Ratification of Company’s independent registered public accounting firm for the ensuing year 11,693,068 114,287 32,495 0”

Idaho Strategic Resources, Inc. shareholders approved Election of nominees to the Board of Directors to serve until the 2027 annual meeting at the 2026-06-10 meeting.

“Proposal 1 – Election of Directors John Swallow 6,846,371 78,994 4,914,485 Grant Brackebusch 6,329,188 596,177 4,914,485 Kevin Shiell 5,924,575 1,000,790 4,914,485 Richard Beaven 5,938,889 986,476 4,914,485 Carolyn Turner 6,475,580 449,785 4,914,485”

ADAMAS TRUST, INC. shareholders approved Approval of an Amendment to the Company’s 2017 Equity Incentive Plan at the 2026-06-11 meeting.

“the stockholders of the Company approved, among other things, the Third Amendment (the “Third Amendment”) to the Adamas Trust, Inc. 2017 Equity Incentive Plan”

ADAMAS TRUST, INC. shareholders approved To approve, on an advisory basis, the compensation of the Company’s named executive officers. at the 2026-06-11 meeting.

“Proposal 2: To approve, on an advisory basis, the compensation of the Company’s named executive officers. For Against Abstain Broker Non-Votes 51,685,136 3,029,838 280,882 14,239,657”

ADAMAS TRUST, INC. shareholders approved To elect seven directors to the Company’s Board of Directors. at the 2026-06-11 meeting.

“Proposal 1: To elect seven directors to the Company’s Board of Directors. Name For Against Abstain Broker Non-Votes Eugenia R. Cheng 54,343,841 509,074 142,941 14,239,657”

Alight, Inc. / Delaware shareholders approved Approval of a series of four alternate amendments to the Alight Charter to authorize the Board to effect reverse stock splits of the outstanding shares of common stock at ratios of 1-for-10, 1-for-20, 1-for-30 and 1-for-40 and corresponding decreases in authorized shares at the 2026-06-10 meeting.

“Proposal No. 6 – Approval of a series of four alternate amendments to the Alight Charter to authorize the Board to effect reverse stock splits of the outstanding shares of common stock at ratios of 1-for-10, 1-for-20, 1-for-30 and 1-for-40 and corresponding decreases in authorized shares: The stockholders approved this proposal.”

Alight, Inc. / Delaware shareholders approved Approval of an amendment to the Alight Charter to provide for the elimination of certain officers’ personal liability for monetary damages stemming from breaches of the duty of care as permitted by Section 102(b)(7) of the General Corporation Law of the State of Delaware at the 2026-06-10 meeting.

“Proposal No. 5 – Approval of an amendment to the Alight Charter to provide for the elimination of certain officers’ personal liability for monetary damages stemming from breaches of the duty of care as permitted by Section 102(b)(7) of the General Corporation Law of the State of Delaware: The stockholders approved this proposal.”

Alight, Inc. / Delaware shareholders approved Approval of an amendment to the Company’s Certificate of Incorporation (the “Alight Charter”) to declassify the Company’s Board of Directors (the “Board”) at the 2026-06-10 meeting.

“Proposal No. 4 – Approval of an amendment to the Company’s Certificate of Incorporation (the “Alight Charter”) to declassify the Company’s Board of Directors (the “Board”): The stockholders approved this proposal.”

Alight, Inc. / Delaware shareholders approved Approval, on an advisory (non-binding) basis, of the 2025 compensation paid to the Company’s named executive officers at the 2026-06-10 meeting.

“Proposal No. 3 - Approval, on an advisory (non-binding) basis, of the 2025 compensation paid to the Company’s named executive officers: The stockholders approved this proposal.”

Alight, Inc. / Delaware shareholders approved Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-10 meeting.

“Proposal No. 2 - Ratification of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026: The stockholders approved this proposal.”

Alight, Inc. / Delaware shareholders approved Election of Class II directors at the 2026-06-10 meeting.

“Proposal No. 1 - Election of directors: Each of the Class II directors listed below were elected to serve terms expiring at the 2029 Annual Meeting of Stockholders of the Company and until his successor has been duly elected and qualified, except in the case of such director's earlier death, resignation, retirement, disqualification, removal or incapacity.”

Korro Bio, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2026-06-10 meeting.

“Korro’s stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm”

Korro Bio, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-10 meeting.

“Korro’s stockholders approved, in a non-binding, advisory vote, the compensation of Korro’s named executive officers”

Korro Bio, Inc. shareholders approved Election of Class I Directors at the 2026-06-10 meeting.

“Korro’s stockholders elected each of Nessan Bermingham and Rachel Meyers as Class I directors”

Green Plains Inc. shareholders approved Advisory vote to approve the Company’s executive compensation at the 2026-06-05 meeting.

“4. Proposal to cast an advisory vote to approve the Company’s executive compensation.”

Green Plains Inc. shareholders approved Proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accountants for the year ending December 31, 2026 at the 2026-06-05 meeting.

“3. Proposal to ratify the selection of KPMG LLP as the Company’s independent registered public accountants for the year ending December 31, 2026.”

Green Plains Inc. shareholders approved Proposal to approve an amendment to the Company’s 2019 Equity Incentive Plan (the “Plan”) to increase the aggregate number of shares that may be issued under the Plan as stock-based awards from 5,710,000 to 7,710,000 and amend certain other provisions at the 2026-06-05 meeting.

“2. Proposal to approve an amendment to the Company’s 2019 Equity Incentive Plan (the “Plan”) to increase the aggregate number of shares that may be issued under the Plan as stock-based awards from 5,710,000 to 7,710,000 and amend certain other provisions.”

Green Plains Inc. shareholders approved Election of nine directors each to serve a one-year term expiring at the 2027 annual meeting at the 2026-06-05 meeting.

“Green Plains Inc. (the “Company”) held its 2026 annual meeting of shareholders on June 5, 2026. All matters voted on were approved. The numbers of shares cast for, against or withheld are as follows: 1. Proposal to elect nine directors, each to serve a one-year term that expires at the 2027 annual meeting.”

Legence Corp. shareholders approved Ratification of the Appointment of Deloitte & Touche LLP as the Company’s Independent Registered Public Accounting Firm for Fiscal Year 2026 at the 2026-06-11 meeting.

“Proposal 5: Ratification of the Appointment of Deloitte & Touche LLP as the Company’s Independent Registered Public Accounting Firm for Fiscal Year 2026 FOR AGAINST ABSTAIN 100,320,150 17,381 5,044 As a result, the Company’s appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.”

Legence Corp. shareholders approved Approval of the Legence Corp. 2026 Employee Stock Purchase Plan at the 2026-06-11 meeting.

“Proposal 4: Approval of the Legence Corp. 2026 Employee Stock Purchase Plan FOR AGAINST ABSTAIN BROKER NON-VOTES 98,024,042 4,856 219,832 2,093,845 As a result, the ESPP was approved.”

Legence Corp. shareholders approved Approval, on a Non-Binding Advisory Basis, of the Frequency of Future Advisory Votes on NEO Compensation at the 2026-06-11 meeting.

“Proposal 3: Approval, on a Non-Binding Advisory Basis, of the Frequency of Future Advisory Votes on NEO Compensation 1 YEAR 2 YEARS 3 YEARS ABSTAIN BROKER NON-VOTES 97,839,229 4,933 400,441 4,127 2,093,845 As a result, the frequency of every one year for future advisory votes on NEO compensation was approved on a non-binding advisory basis.”

Legence Corp. shareholders approved Approval, on a Non-Binding Advisory Basis, of 2026 Named Executive Officer Compensation at the 2026-06-11 meeting.

“Proposal 2: Approval, on a Non-Binding Advisory Basis, of 2026 Named Executive Officer Compensation FOR AGAINST ABSTAIN BROKER NON-VOTES 95,847,463 2,119,206 282,061 2,093,845 As a result, the 2026 compensation of the Company’s named executive officers (“NEOs”) was approved on a non-binding advisory basis.”

Legence Corp. shareholders approved Election of Class I Directors at the 2026-06-11 meeting.

“Proposal 1: Election of Class I Directors NOMINEES FOR WITHHELD BROKER NON-VOTES David Coghlan 96,766,776 1,481,954 2,093,845 Bilal Khan 77,227,300 21,021,430 2,093,845 As a result, the above individuals were elected to serve as Class I directors on the Company’s Board of Directors until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified.”

LINDBLAD EXPEDITIONS HOLDINGS, INC. shareholders approved Ratification of the Appointment of the Company’s Independent Registered Certified Public Accounting Firm for Fiscal Year 2026 at the 2026-06-10 meeting.

“Proposal No. 3. The Ratification of the Appointment of the Company ’ s Independent Registered Certified Public Accounting Firm for Fiscal Year 2026 : The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered certified public accounting firm for fiscal year 2026.”

LINDBLAD EXPEDITIONS HOLDINGS, INC. shareholders approved Advisory Resolution on Executive Compensation at the 2026-06-10 meeting.

“Proposal No. 2. Advisory Resolution on Executive Compensation : The Company’s stockholders approved, on an advisory basis, the 2025 compensation of the Company’s named executive officers disclosed in the Executive Compensation section and the related tables, notes and narrative in the Proxy Statement.”

LINDBLAD EXPEDITIONS HOLDINGS, INC. shareholders approved Election of Directors at the 2026-06-10 meeting.

“Proposal No. 1. Election of Directors : The Company’s stockholders elected L. Dyson Dryden, John M. Fahey, Catherine B. Reynolds and Andy Stuart as Class B directors to serve terms expiring at the annual meeting of stockholders to be held in 2029, until their successors have been elected and qualified.”

Vertex, Inc. shareholders approved Election of directors at the 2026-06-10 meeting.

“The following nominees were elected as directors, each to hold office until the 2029 Annual Meeting of Stockholders, or the earlier to occur of his or her death, disqualification, resignation, or removal or the appointment of his or her successor, by the vote set forth below: Nominee For Withheld Broker Non-Votes Eric Andersen 815,856,932.000 23,184,805.000 7,910,119.000 David DeStefano 835,946,632.000 3,095,105.000 7,910,119.000 Christopher Young 837,340,096.000 1,701,641.000 7,910,119.000”

INNOVATE Corp. shareholders approved Ratification of the appointment of BDO USA, P.C., as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting.

“Proposal 4: Ratification of the appointment of BDO USA, P.C., as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 (“ Accounting Firm Proposal ”) The stockholders voted to ratify the appointment of BDO USA, P.C., as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”

INNOVATE Corp. shareholders approved Approval of Amendment to Second Amended and Restated 2014 Omnibus Equity Award Plan to increase the number of shares of Common Stock available for issuance at the 2026-06-11 meeting.

“Proposal 3: Approval of Amendment to Second Amended and Restated 2014 Omnibus Equity Award Plan to increase the number of shares of Common Stock available for issuance thereunder (“ Second A&R 2014 Plan Proposal ”) The stockholders voted to approve an amendment to the Company’s Second Amended and Restated 2014 Omnibus Equity Award Plan to increase the number of shares of Common Stock available for issuance thereunder.”

INNOVATE Corp. shareholders approved Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers at the 2026-06-11 meeting.

“Proposal 2: Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers (“ Say on Pay Vote ”) The stockholders voted to approve the non-binding, advisory proposal on the compensation of the Company’s named executive officers.”

INNOVATE Corp. shareholders approved Election of Directors - four nominees at the 2026-06-11 meeting.

“Proposal 1: Election of Directors The stockholders voted to elect the following four nominees as members of the Board of Directors of the Company, each to hold office until the Company’s 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified.”

Pacira BioSciences, Inc. shareholders approved Approval of the Company’s Amended and Restated 2014 Employee Stock Purchase Plan at the 2026-06-09 meeting.

“Proposal 5 — Approval of the Company’s Amended and Restated 2014 Employee Stock Purchase Plan. For Against Abstain Broker Non-Votes 29,089,928 3,497,653 55,974 452,437”

Pacira BioSciences, Inc. shareholders rejected Approval of the Company’s Amended and Restated 2011 Stock Incentive Plan at the 2026-06-09 meeting.

“Proposal 4 — Approval of the Company’s Amended and Restated 2011 Stock Incentive Plan. For Against Abstain Broker Non-Votes 14,178,418 18,405,754 59,383 452,437”

Pacira BioSciences, Inc. shareholders approved Advisory vote to approve the compensation of the Company’s named executive officers at the 2026-06-09 meeting.

“Proposal 3 — Advisory vote to approve the compensation of the Company’s named executive officers. For Against Abstain Broker Non-Votes 19,513,224 13,073,321 57,010 452,437”

Pacira BioSciences, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-09 meeting.

“Proposal 2 — Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Abstain 32,908,044 138,246 49,702”

Pacira BioSciences, Inc. shareholders approved Election of three Class III directors at the 2026-06-09 meeting.

“Proposal 1 — Election of three Class III directors to hold office until the 2029 annual meeting of stockholders, and until their respective successors have been duly elected and qualified. Company’s Nominees Nominee: For Withhold Christopher J. Christie 24,963,961 7,675,321 Samit Hirawat 27,950,304 4,688,937 Thomas Wiggans 28,044,841 4,594,438 DOMA Perpetual Capital Management LLC’s Nominees Nominee: For Withhold Oliver Benton Curtis III 4,614,368 28,024,482 Eric de Armas 4,861,350 27,777,500 Christopher Dennis 4,430,726 28,208,124”

VERACYTE, INC. shareholders approved Approval of amendment to the 2023 Equity Incentive Plan to increase the number of shares reserved for issuance by 3,500,000 at the 2026-06-10 meeting.

“The stockho lders approved the 2023 Plan Amendment.”

VERACYTE, INC. shareholders approved Non-binding advisory vote on the compensation of the Company's named executive officers at the 2026-06-10 meeting.

“The stockho lders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.”

VERACYTE, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2026 at the 2026-06-10 meeting.

“The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”

VERACYTE, INC. shareholders approved Election of nine directors to serve until the 2027 annual meeting of stockholders at the 2026-06-10 meeting.

“Each of the nine nominees for director was elected to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified.”